INVESTING IN THE FUTURE OF CANNABIS

PharmaCielo Provides Details for Fourth Quarter and Year-End 2019 Results Conference Call

TORONTO, April 29, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTCQX:PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., advised today that it will be holding its fourth quarter and fiscal 2019 financial results conference call on April 30, 2020 at 9:00 a.m. ET. While the Company's usual year-end audit process was delayed as a result of the ongoing COVID-19 pandemic, the Company will be filing its financial results tonight, April 29, 2020, consistent with the regulatory schedule.

CONFERENCE CALL

PharmaCielo will host a conference call on Thursday, April 30th, 2020, at 9:00 a.m. ET to discuss its financial results and provide investors with key business highlights. The call will be chaired by David Attard, CEO, David Gordon, CCO and Scott Laitinen, CFO.

CONFERENCE CALL DETAILS

Date: April 30th, 2020 | Time: 9:00 a.m. ET

Participant Dial-in: 416-764-8650 or 1-888-664-6383

Replay Dial-in: 416-764-8677 or 1-888-390-0541

(Available for 2 weeks – Expiring May 14th, 2020)

Conference ID: 58230664

Playback #: 230664

Listen to webcast: pcloevent.on24.com

About PharmaCielo

PharmaCielo Ltd. (TSXV: PCLO, OTCQX: PCLOF) is a global company, headquartered in Canada, with a focus on ethical and sustainable processing and supplying of all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. PharmaCielo's principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its nursery and propagation centre located in Rionegro, Colombia.

SOURCE PharmaCielo Ltd.

For further information: Investor Relations Inquiries: For further information: David Gordon, Chief Corporate Officer, +1 416-864-6116, www.PharmaCielo.com; Investor Inquiries: investors@PharmaCielo.com; Media Relations: International: Gal Wilder, Cohn & Wolfe, +1 647-259-3261, gal.wilder@cohnwolfe.ca